FDA warning letters
A warning letter is FDA's formal notice that a company broke the law, usually found during an inspection. The company has 15 working days to reply. Letters that go unanswered lead to seizures, import bans or court orders.
1,276 letters match. Newest first.
-
DrugsClean Solutions LLC
FDA warned Clean Solutions LLC that its OTC hand soaps and sanitizer were adulterated because it released drugs without component or finished-product testing.
High risk -
DrugsAzurity Pharmaceuticals, Inc.
FDA warned Azurity Pharmaceuticals over unapproved FIRST drug kits and manufacturing quality failures at its Wilmington, MA plant.
High risk -
DrugsNomida.biz
FDA warned Nomida.biz over its website selling unapproved and misbranded semaglutide and tirzepatide drugs to U.S. consumers.
High risk -
DrugsAccupack Midwest, Inc.
Accupack Midwest, an over-the-counter drug contract manufacturer, lacked adequate water controls and process validation.
High risk -
DrugsWittman Pharma, Inc.
FDA warns Wittman Pharma, an OTC drug maker in Brooksville, Florida, that weak quality oversight and contaminated water make its products adulterated.
High risk -
DrugsAerosol and Liquid Packaging, Inc.
FDA warns Aerosol and Liquid Packaging on CGMP failures and unapproved antiseptic spray claims.
High risk -
DrugsQuality CDMO, Inc.
FDA warned Quality CDMO that its prescription skin and scalp drugs are unapproved and lack FDA-approved applications.
High risk -
DrugsAromas Para El Alma S.A.
Aromas Para El Alma, a Costa Rica drug manufacturer, made EREWHON hand sanitizer/spray subpotent and broke manufacturing rules.
High risk -
DrugsEnviroServe Chemicals & Cleaners Ltd.
EnviroServe's SOPURE hand sanitizer had manufacturing-quality violations and was sold as an unapproved, misleadingly labeled drug.
High risk -
DrugsGreco Gas, Inc.
Greco Gas, Inc. released medical gases without identity or purity testing and without quality oversight.
High risk -
DrugsTJA Health, LLC
FDA warns TJA Health LLC over unsafe drug manufacturing of toothpaste and mouth rinse due to untested components and poor quality control.
High risk -
DrugsAvaria Health & Beauty Corp.
FDA warns Canadian maker Avaria Health & Beauty over CGMP failures in OTC drug products, including skipped ingredient identity testing.
High risk -
DrugsRoot Bioscience Brands, LLC dba Naternal
FDA warned Naternal that its CBD oils, gummies, and pet hemp oil are unapproved drugs due to drug claims.
High risk -
DrugsZydus Lifesciences Limited
FDA warned Zydus Lifesciences over cross-contamination and glass particles in its injectable drugs, leading to recalls.
High risk -
DrugsOrean Personal Care Ltd.
FDA warned Orean Personal Care Ltd. that repeat manufacturing failures make its OTC drugs adulterated.
High risk -
DrugsRegenerative Processing Plant, LLC
FDA warns Regenerative Processing Plant over unapproved, misbranded Regener-Eyes eye drops and serious sterile manufacturing violations.
High risk -
DrugsMexHealth LLC d/b/a Al Natural E-Shop
FDA warned MexHealth LLC d/b/a Al Natural E-Shop that its Ossos-Sans supplement is an unapproved, misbranded drug containing hidden diclofenac and methocarbamol.
High risk -
DrugsSoloVital
FDA says SoloVital's Umary supplement is an unapproved, misbranded drug containing hidden diclofenac and omeprazole.
High risk -
DrugsEverymarket Inc.
FDA warned Everymarket Inc. that its website sells two unapproved drugs, one with hidden dexamethasone and chlorpheniramine.
High risk -
DrugsJulio R. Flamini, M.D./Clinical Integrative Research Center of Atlanta
FDA warns an Atlanta clinical investigator after a 15-year-old trial subject was given about 10 times the protocol dose.
High risk -
DrugsKaylaan LLC
FDA warns Kaylaan LLC that its fluoride toothpaste tablets were made without release testing, raw material identity testing, and adequate CGMP controls.
High risk -
DrugsAnuMed International, LLC
FDA warned AnuMed International about unapproved drugs, misleading FDA claims, and manufacturing quality failures.
High risk -
DrugsCARsgen Therapeutics Corporation
FDA warns CARsgen over CGMP violations for investigational CAR T cell products at Durham facility.
High risk -
DrugsEyePoint Pharmaceuticals, Inc.
FDA cited EyePoint Pharmaceuticals in Watertown, MA for manufacturing-quality violations affecting its YUTIQ eye implant, including inadequate investigations and process controls.
High risk -
DrugsMedia Networks Sydney Pty Limited
Media Networks Sydney failed to properly list Mylanta 2go Antacid and Microlax Enema with FDA, making them misbranded.
Low -
DrugsEugia Pharma Specialities Limited
FDA cited Eugia Pharma Specialities for CGMP violations at its India sterile injectable plant, including falsified records and contamination risks.
High risk -
DrugsIntercos Europe S.p.A
FDA warned Intercos Europe S.p.A over current good manufacturing practice violations in OTC sunscreen drugs, including missing glycerin DEG/EG testing and poor investigations.
High risk -
DrugsLS Promotions Inc.
LS Promotions Inc. failed to adequately test and validate its OTC sunscreens, lip balm and hand sanitizer, making them adulterated drugs.
High risk -
DrugsNowrez & Ismail Shukri Company
FDA warns Jordanian OTC drug maker Nowrez & Ismail Shukri over CGMP violations and import alert.
High risk -
DrugsCentral Admixture Pharmacy Services, Inc.
FDA warns Central Admixture Pharmacy Services over sterile compounded drugs, contamination risks, and quality failures at its San Diego site.
High risk -
DrugsGuangzhou Baiyunshan Jingxiutang Pharmaceutical Co. Ltd.
FDA warned Guangzhou Baiyunshan Jingxiutang Pharmaceutical over current good manufacturing practice violations in over-the-counter drug manufacturing, including inadequate specs and microbial testing.
High risk -
DrugsOmega Tech Labs LLC
Omega Tech Labs in Boise, Idaho, released microbially contaminated combination drug-device product and failed manufacturing rules.
High risk -
DrugsVelocity Pharma LLC
Velocity Pharma distributed eye drop drugs made by contract manufacturers with serious manufacturing and sanitation violations.
High risk -
DrugsWalmart, Inc.
FDA warned Walmart over selling an unapproved 90% lactic acid chemical peel drug that can cause burns.
High risk -
DrugsISIS.GOLD
ISIS.GOLD sells TCA 100% and Whitening SA chemical peels as unapproved new drugs without FDA-approved applications.
High risk -
DrugsSkin Beauty Solutions
FDA warns Skin Beauty Solutions that its chemical peel products are unapproved new drugs sold with acne and scar treatment claims.
High risk -
DrugsRepare Skincare
Repare Skincare sold unapproved TCA and glycolic acid chemical peels online with drug claims, FDA says.
High risk -
DrugsMatte Beauty
FDA warned Matte Beauty that its chemical peel drugs are unapproved and sold with treatment claims.
High risk -
DrugsAmazon.com, Inc.
FDA warns Amazon over selling two unapproved chemical peel drugs that can burn skin.
High risk -
DrugsV10Suppliers.com
FDA warned UK website V10Suppliers.com for selling unapproved, misbranded opioid drugs to U.S. consumers.
High risk -
DrugsBrassica Pharma Pvt. Ltd.
FDA warns Brassica Pharma over fabricated sterility and environmental data and poor aseptic controls for sterile drugs.
High risk -
DrugsGenuine Virgin Aloe Corp dba Triderma
FDA warned Triderma, an Anaheim OTC skin cream maker, of CGMP violations after a January 2024 inspection.
High risk -
DrugsYahon Enterprise Co., Ltd.
FDA warned Yahon Enterprise over manufacturing quality failures for OTC antiseptic wipes after a December 2023 inspection.
High risk -
DrugsJiangsu Hengrui Pharmaceuticals Co., Ltd.
FDA found data integrity failures and inadequate sterile manufacturing controls at Jiangsu Hengrui Pharmaceuticals' drug facility.
High risk -
DrugsCholrem Pty Ltd dba Cholrem and Cholrem Pharmaceuticals
FDA warned Cholrem over selling unapproved RemChol enema products with claims to treat atherosclerosis and reverse heart disease.
High risk -
DrugsYangZhou SuXiang Medical Instrument Co., Ltd.
FDA warns YangZhou SuXiang Medical Instrument over manufacturing quality failures and import alert for OTC drugs.
High risk -
DrugsMax Chemical Inc.
FDA warned Max Chemical Inc. in San Juan, Puerto Rico, that its OTC drug manufacturing violated CGMP, making its drugs adulterated.
High risk -
DrugsARG Laboratories, Inc.
FDA found ARG Laboratories released failing over-the-counter drug lots, lacked manufacturing controls, and marketed two unapproved pain creams.
High risk -
DrugsArt of Beauty Company, Inc.
FDA warned Art of Beauty over manufacturing-rule violations in OTC hand sanitizer, including missing component and finished-product testing.
High risk -
DrugsreBom Co., Ltd.
reBom failed current good manufacturing practice for OTC drugs, including inadequate stability and component testing.
High risk